Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%

doi:10.2147/OPTH.S15379

Paper

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%

Published Jan 13, 2011 · J. Greiner, Kimberly Edwards-Swanson, A. Ingerman

Clinical Ophthalmology (Auckland, N.Z.)

Q1 SJR score

48

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Purpose To evaluate the effectiveness of alcaftadine 0.05%, 0.1%, and 0.25% ophthalmic solutions in treating the signs and symptoms of allergic conjunctivitis when compared with olopatadine hydrochloride 0.1% and placebo using the conjunctival allergen challenge (CAC) model. Methods One hundred and seventy subjects were randomized and 164 subjects completed all visits. CAC was performed to determine and confirm subjects’ eligibility at visits 1 and 2, respectively. The CAC was repeated at visit 3 (day 0 ± 3), 16 hours after study medication instillation, and at visit 4 (day 14 ± 3), 15 minutes after instillation. Ocular itching and conjunctival redness were evaluated after an allergen challenge, along with several secondary endpoints. Results Alcaftadine 0.25% and olopatadine 0.1% treatments exhibited significantly lower mean scores compared with placebo for ocular itching and conjunctival redness at visits 3 and 4. Most adverse events were self-limiting and mild in severity. No serious treatment-related adverse events occurred. Conclusion Treatment with alcaftadine 0.25% ophthalmic solution resulted in mean differences of >1 unit (ocular itching) and approximately >1 unit (conjunctival redness), which was significant (P < 0.001) compared with placebo treatment. All doses of alcaftadine were safe and well tolerated in the population studied.

RCT

Study Snapshot

Alcaftadine 0.25% ophthalmic solution significantly reduces ocular itching and conjunctival redness compared to placebo, making it a safe and well-tolerated treatment for allergic conjunctivitis.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%

Sign up to use Study Snapshot

References

Role of histamine H(4) receptor in allergic conjunctivitis in mice.

H4 receptor antagonists may be effective in treating allergic conjunctivitis, which is not inhibited by histamine H1 receptor antagonists.

The histamine H4 receptor antagonist JNJ7777120 induces increases in the histamine content of the rat conjunctiva

The H4 receptor antagonist JNJ7777120 increases histamine content in rat conjunctiva, suggesting a functional H4 receptor in the rat eye and its role in ocular inflammation.

Efficacy of Once-Daily Olopatadine 0.2% Ophthalmic Solution Compared to Twice-Daily Olopatadine 0.1% Ophthalmic Solution for the Treatment of Ocular Itching Induced by Conjunctival Allergen Challenge

Olopatadine 0.2% and 0.1% ophthalmic solutions effectively prevent ocular itching in allergic conjunctivitis, with no adverse events observed during drug therapy.

Ocular allergic disease: mechanisms, disease sub-types, treatment.

Ocular allergy affects over 20% of the general population in the US and is treated with various medications and therapies, with new frontiers in mechanisms, therapy, and office management.

Conjunctival allergen challenge: Models in the investigation of ocular allergy

Conjunctival allergen challenge models have significantly improved the identification of new ocular allergy treatments by enabling efficient screening of potential allergens in the eye.

Citations

Method Development and Validation of Alcaftadine Drug in Bulk and Dosage Form by RP-HPLC

A new, sensitive, and robust RP-HPLC method has been developed for determining Alcaftadine in bulk drug and pharmaceutical dosage forms, offering a simple and precise solution for routine analysis in industry.

Alcaftadine 0.25% Vs Olapatadine 0.2% Ophthalmic Solutions in Allergic Conjunctivitis: A Study in a Clinical Setting in South India

Alcaftadine 0.25% ophthalmic solution is more effective than Olapatadine 0.2% in treating allergic conjunctivitis symptoms, with both being safe and effective.

A comparative study of efficacy and safety of alcaftadine 0.25% versus olopatadine hydrochloride 0.2% in allergic conjunctivitis at a tertiary care hospital

Alcaftadine 0.25% is more effective in reducing ocular signs and symptoms of allergic conjunctivitis than olopatadine hydrochloride 0.2%, with minimal side-effects.

Stability-indicating UPLC, TLC-densitometric and UV-spectrophotometric methods for alcaftadine determination.

The developed stability-indicating methods effectively determine alcaftadine in ophthalmic solution and plasma samples, with accuracy comparable to previously reported methods.

Evaluation Of Prescribing Pattern For Various Types Of Allergic Conjunctivitis In Ophthalmology Outpatient Department Of Nalanda Medical College: A Tertiary Care Teaching Hospital Of Bihar

Seasonal allergic conjunctivitis is the most common type, followed by Vernal keratoconjunctivitis, PAC, AKC, CA, and GPC, with dual-acting antihistaminic/mast cell stabilizing drugs being most commonly prescribed.